Medco Health Solutions Faces Second DoJ Probe In Five Years; Latest Involves AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
Medco Health Solutions and AstraZeneca have received subpoenas from the DoJ for information involving arrangements pertaining to four AstraZeneca drugs.
You may also be interested in...
DoJ Bull’s Eye: Off-Label Promotion, Formulary Placements, FCPA Violations Remain Targets
A Pfizer attorney says government saber rattling over individual liability does not mean there will be a spike in individual prosecutions; Pfizer’s cooperation with the government helped it avoid criminal resolution in a Foreign Corrupt Practices Act settlement.